Primary medical therapy for acromegaly.
There is now considerable evidence that the clinical outcome in patients with acromegaly can be improved very substantially by means of better surgical expertise and effective medical therapies used in a flexible and innovative manner. Medical therapy alone in patients who have not undergone surgery or radiotherapy (primary medical therapy) offers the prospect of near normalisation of GH/IGF-I levels together with substantial tumour shrinkage in a significant number of patients.
Sheppard
Michael C
MC
Department of Medicine, Division of Medical Sciences, University of Birmingham, Birmingham, UK. M.C.Sheppard@bham.ac.uk
D000172:Acromegaly / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D000236:Adenoma / Q000188:drug therapy / Q000401:mortality / Q000601:surgery; D002769:Cholelithiasis / Q000139:chemically induced; D003131:Combined Modality Therapy; D003692:Delayed-Action Preparations; D013006:Growth Hormone / Q000037:antagonists & inhibitors / Q000378:metabolism; D019382:Human Growth Hormone / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D015282:Octreotide / Q000627:therapeutic use; D010911:Pituitary Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000601:surgery; D011986:Receptors, Somatotropin / Q000037:antagonists & inhibitors; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome
D003692:Delayed-Action Preparations; D011986:Receptors, Somatotropin; D019382:Human Growth Hormone; D013004:Somatostatin; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; C406545:pegvisomant; D015282:Octreotide